PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC THERAPEUTICS, INC. (PTCT) reported that director Michael Schmertzler, through Section Six Partners, L.P., filed a Form 4 for indirect sales of a total of 20,000 shares of common stock on September 9–10, 2026 under a written Rule 10b5-1 trading plan adopted on May 14, 2026.
The shares are held by Section Six Partners, L.P., where Schmertzler is a general and limited partner, and he disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.
PTC Therapeutics, Inc. (PTCT) has a notice of proposed resale of its common stock filed on behalf of Section Six Partners, L.P., an affiliate of a director, under Rule 144. The notice covers 40,000 shares of common stock of PTCT, with an aggregate market value of $2,740,000 as of September 9, 2026. These shares were originally acquired on June 25, 2013 through an automatic conversion of preferred stock into common stock upon PTCT’s IPO, with the preferred stock purchased from the issuer for cash. In the prior three months, Section Six Partners, L.P. reported four separate sales of 12,500 shares each of PTCT common stock. Director Michael Schmertzler, a general and limited partner of Section Six Partners, L.P., disclaims beneficial ownership of the partnership’s shares except to the extent of his pecuniary interest.
PTC THERAPEUTICS, INC. (PTCT) reported that director Michael Schmertzler, through Section Six Partners, L.P., with indirect ownership, sold a total of 25,000 shares of common stock on August 26–27, 2026 under a written Rule 10b5-1 plan adopted on May 14, 2026. The sales were open-market transactions at weighted average prices around $71.55–$73.18 per share, each executed in multiple trades within disclosed price ranges. Separately, Schmertzler directly held 163,266 shares of common stock as of August 26, 2026. He disclaims beneficial ownership of the Section Six Partners, L.P. shares except to the extent of his pecuniary interest.
PTC Therapeutics, Inc. (PTCT) agreed to acquire from Sangamo Therapeutics all assets primarily related to ST-920, a one-time AAV gene therapy product candidate for Fabry disease, and assume certain specified liabilities. The consideration includes an upfront cash payment of $111 million plus up to $100 million in contingent FDA-approval milestones.
The milestones comprise $80 million upon FDA accelerated approval of a BLA for ST-920 based on Sangamo’s STAAR Studies and $20 million upon full FDA approval based on the same studies. The transaction follows PTCT’s selection as winning bidder for ST-920 in Sangamo’s Chapter 11 bankruptcy auction.
Closing is subject to customary conditions, including a Delaware Bankruptcy Court order approving the acquisition, expiration or termination of the Hart-Scott-Rodino waiting period, and each party’s representations and covenants being satisfied. Either party may terminate if closing has not occurred by October 15, 2026. A Bankruptcy Court hearing to consider approval is scheduled for September 10, 2026.
PTC THERAPEUTICS, INC. (PTCT) received an amended Rule 144 notice indicating that Section Six Partners, L.P., identified as an affiliate of a director, plans to sell up to 50,000 shares of common stock through Merrill Lynch on NASDAQ. The amendment revises the seller’s name and related securities information. The shares to be sold were acquired on 06/25/2013 via automatic conversion of preferred stock into common stock upon the company’s IPO, from the issuer for cash. As of 08/19/2026, there were 83,460,802 shares of common stock outstanding. Director Michael Schmertzler, a general and limited partner of Section Six Partners, disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
PTC THERAPEUTICS, INC. (PTCT) director Michael Schmertzler reported indirect sales of an aggregate 25,000 shares of common stock on August 19–20, 2026. The sales were made by Section Six Partners, L.P., where he is a general and limited partner, pursuant to a written Rule 10b5-1 plan adopted on May 14, 2026. The reported weighted average prices ranged from the low $70s to the mid $73s per share across multiple trade buckets. Schmertzler reports separate direct ownership of 163,266 shares of PTCT common stock and disclaims beneficial ownership of the partnership-held shares except to the extent of his pecuniary interest.
PTC THERAPEUTICS, INC. (PTCT) executive vice president and CLO Mark Elliott Boulding exercised stock options for 2,813 shares of common stock at an exercise price of $25.69 per share and then sold those 2,813 shares in two tranches at weighted average prices of $72.39 and $72.90 on August 17, 2026. Following the option exercise, he held 16,876 stock options under that award, which was granted on February 15, 2024 and vests over four years. These transactions were effected pursuant to a written Rule 10b5-1 plan adopted on September 10, 2025.
PTC THERAPEUTICS, INC. (PTCT) is the issuer for a planned resale of its common stock under Rule 144. Michael Schmertzler, for whose account the sale will occur, through Section Six Partners, LP, has notified of an intended sale of 50,000 common shares, expected to be executed in the open market via Merrill Lynch on NASDAQ. The shares were acquired on 07/04/2012. Shares outstanding were 83,460,802 as of 08/19/2026; this is a baseline figure, not the amount being sold.
PTC Therapeutics insider Mark Boulding filed a notice to sell 2,813 shares of common stock on or after August 17, 2026, following a stock option exercise for cash. The shares are held at Fidelity Brokerage Services and are listed on NASDAQ. The filing also lists prior sales of common stock during the past three months.
Those earlier transactions include 10,522 shares sold on June 17, 2026 and 5,079 shares sold on July 6, 2026, with the filing reporting the corresponding dollar values for each sale.
PTC Therapeutics, Inc. plans to acquire ST-920, a BLA-stage, one-time administered AAV gene therapy for Fabry disease, from Sangamo Therapeutics after being selected as winning bidder in a competitive bankruptcy auction. Terms include a $111 million upfront payment and up to $100 million in contingent milestones tied to U.S. FDA approvals.
The transaction is subject to definitive documentation, bankruptcy court approval, antitrust review and other customary closing conditions, and is expected to close in late third or early fourth quarter 2026. A rolling BLA submission for accelerated approval is expected to be completed in the fourth quarter of 2026, with a potential commercial launch in 2027 and additional regulatory filings planned outside the United States.